Tilray (TLRY)
NASDAQ:TLRY
Want to see TLRY full AI Analyst Report?
TLRY Stock Chart & Stats
$6.86
-$0.07(-5.17%)
At close: 4:00 PM EST
$6.86
-$0.07(-5.17%)
Day’s Range― - ―
52-Week Range$3.50 - $23.20
Previous CloseN/A
Volume22.72M
Average Volume (3M)3.53M
Market Cap
$565.73M
Enterprise Value$680.58M
Total Cash (Recent Filing)$219.93M
Total Debt (Recent Filing)$317.08M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Jul 29, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.70
Shares Outstanding119,604,225
10 Day Avg. Volume4,064,873
30 Day Avg. Volume3,528,505
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.18
Price to Sales (P/S)0.34
P/FCF Ratio-2.17
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue0.58
Enterprise Value/Gross Profit2.08
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$7.94Price Target Upside15.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$1.10B
Bulls Say, Bears Say
Bulls Say
International Cannabis GrowthRapid, high-single-digit volume and sales growth in international medical markets demonstrates durable geographic diversification and deeper penetration in regulated channels. Strong Germany performance and GMP-capable manufacturing position Tilray to capture long-term regulated market share and reduce reliance on a single market cycle.
Distribution & Pharmacy ReachA larger distribution business with meaningful pharmacy expansion builds recurring, high-frequency revenues and durable route-to-market advantages. Scale and partner network in Europe create barriers for competitors and improve ability to roll out new products across medical channels over the medium term.
Liquidity Improvement & Cost SavingsA strengthened cash position and near-net-cash funding buffer materially reduce immediate refinancing stress, while Project 420's $33M annualized savings (partially realized) structurally improves margins. Together these enhance runway to integrate acquisitions and scale operations without urgent capital raises.
Bears Say
Sustained GAAP Losses & Weak Cash FlowLarge trailing net losses and negative operating and free cash flow show the core business is not yet self-funding. Continued cash burn erodes equity, forces reliance on external financing, and elevates the risk that shareholder value is diluted unless consistent GAAP profitability and positive FCF are achieved.
Beverage Revenue & Margin PressureThe beverage platform faces declining revenue and compressed margins from lower overhead absorption and higher input costs. Given management's strategic emphasis on scaling beverages, persistent mix and cost pressures could delay the unit's path to sustainable cash generation and weigh on consolidated profitability.
Capital-Raising & Dilution RiskReliance on ATM offerings and note-for-stock exchanges reduces debt but increases share count, shifting recovery toward equity-funded growth. Continued dependence on capital markets risks recurring dilution and makes long-term per-share returns contingent on achieving sustained profitability and cash generation.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was $3.50 and its highest was $23.20 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is $565.73M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Jul 29, 2026 which is in 37 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Apr 01, 2026. The company reported -$0.224 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.088.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is >-0.01.
How many shares outstanding does Tilray have?
Tilray has 119,604,225 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -$0.224 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -5.1%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.94 (15.78% Upside)
$7.94 (15.78% Upside)
Blogger Sentiment
Neutral
TLRY Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 359.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $232.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 12.8%
Last 30 Days ▼ 12.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
23.40%
12-Months-Change
Fundamentals
Return on Equity
-92.82%
Trailing 12-Months
Asset Growth
-39.04%
Trailing 12-Months
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted clear operational progress: record quarterly revenue, strong international cannabis momentum, meaningful distribution growth, completed cost-savings programs and strategic beverage partnerships/acquisition that materially expand the company’s scale. Several significant challenges remain — beverage revenue and margin pressure, input cost volatility (aluminum, fuel), working capital-related cash use, regulatory uncertainty in the U.S., and integration work for BrewDog — but management presented concrete actions (hedging, Project 420, SKU rationalization, partnerships) and a strengthened liquidity position. On balance, the positive operational and strategic developments outweigh the near-term headwinds.View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
$7.94
▲(15.78% Upside)
Technical Analysis
Ownership Overview
6.79% Insiders
0.42% Mutual Funds
0.97% Other Institutional Investors
88.31% Public Companies and
Individual Investors